<DOC>
	<DOCNO>NCT02071927</DOCNO>
	<brief_summary>Many tumor cell , contrast normal cell , show require amino acid glutamine produce energy growth survival . To exploit dependence tumor glutamine , CB-839 , potent selective inhibitor first enzyme glutamine utilization , glutaminase , test Phase 1 study patient leukemia . This study open-label Phase 1 evaluation CB-839 subject leukemia . Part 1 dose escalation study identify recommend Phase 2 dose single agent combination azacitidine . Patients enrol Part 2 treat recommended Phase 2 dose . As extension Part 2 , patient relapsed/ refractory newly diagnose AML treat CB-839 combination azacitidine . All patient assess safety , pharmacokinetics ( plasma concentration drug ) , pharmacodynamics ( inhibition glutaminase ) , biomarkers ( biochemical marker may predict responsiveness later study ) , tumor response .</brief_summary>
	<brief_title>Study Glutaminase Inhibitor CB-839 Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion Criteria Diagnosis AML ALL , relapse refractory least 1 prior treatment regimen . Newlydiagnosed patient ≥ 60 year old refuse consider unfit standard chemotherapy regimens stem cell transplantation also eligible . Patients must available approved therapy confer clinical benefit All patient must bone marrow involvement tumor , document blast percentage &gt; 5 % . Peripheral blood blast count must ≤ 30,000 cells/µL . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Adequate hepatic , renal , cardiac function Exclusion Criteria Any current malignancy Patients acute promyelocytic leukemia ( APL ) Treatment unapproved , investigational agent within 21 day first dose study drug Allogeneic hematopoietic stem cell transplant Donor Lymphocyte Infusion within 90 day prior first dose study drug Active GVHD Unable receive medication mouth Major surgery within 28 day Cycle 1 Day 1 Uncontrolled , active infection ; patient know HIV infection/ seropositivity , Hepatitis A , B , C , CMV reactivation Significant neurotoxicity/neuropathy ( Grade 3 high ) within 14 day prior Day 1 Refractory nausea vomit situation may preclude adequate absorption Conditions could interfere treatment procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>leukemia</keyword>
	<keyword>glutaminase</keyword>
	<keyword>glutamine</keyword>
</DOC>